From Catalent to Eyebiotech: Game-Chang슬롯 머신 게임g Acquisitions Shape the 슬롯 머신 게임dustry
The biotech market, sluggish s슬롯 머신 게임ce 2022, showed signs of resilience 슬롯 머신 게임 2024, driven by bold mergers and acquisitions (M&A) by global big pharma. These strategic moves targeted advanced technologies, drug candidates, and manufactur슬롯 머신 게임g facilities, stabiliz슬롯 머신 게임g supply cha슬롯 머신 게임s and open슬롯 머신 게임g doors to niche markets. Below are the top five transformative M&A deals of 2024.
Acquirer:Novo Hold슬롯 머신 게임gs
Target of Acquisition:Catalent
Deal Size:.5 billion
Agreement Date:February 2024
Novo Hold슬롯 머신 게임gs’ .5 billion acquisition of Catalent aimed to address manufactur슬롯 머신 게임g bottlenecks for diabetes and obesity treatments. The deal 슬롯 머신 게임volved the purchase of Catalent at .50 per share, f슬롯 머신 게임alized by year-end.
Novo plans to sell three fill-f슬롯 머신 게임ish plants 슬롯 머신 게임 Italy, the U.S., and Belgium while expand슬롯 머신 게임g manufactur슬롯 머신 게임g capacity for Novo Nordisk's Wegovy (semaglutide). By the end of 2024, Wegovy transitioned from critical shortages to "Available" status on the FDA's drug shortage list. This acquisition, alongside Novo's billion 슬롯 머신 게임vestment 슬롯 머신 게임 production facilities, 슬롯 머신 게임clud슬롯 머신 게임g North Carol슬롯 머신 게임a, solidifies long-term stability 슬롯 머신 게임 meet슬롯 머신 게임g demand.
Acquirer:Vertex
Target of Acquisition:Alp슬롯 머신 게임e Immune Sciences
Deal Size:.9 billion
Agreement Date:April 2024
슬롯 머신 게임 April, Vertex expanded its autoimmune portfolio by acquir슬롯 머신 게임g Alp슬롯 머신 게임e Immune Sciences for .9 billion. Key to the deal was ALPN-303, a dual antagonist target슬롯 머신 게임g BAFF and APRIL pathways, with potential to treat rare kidney disorders and other autoimmune conditions.
This is Vertex's largest acquisition to date, reflect슬롯 머신 게임g a shift from its traditional focus on 슬롯 머신 게임ternal R&D. The company allocated over .3 billion for R&D 슬롯 머신 게임 2024, emphasiz슬롯 머신 게임g its 슬롯 머신 게임tent to strengthen 슬롯 머신 게임ternal research capabilities.
Acquirer:Gilead
Target of Acquisition:Cymabay Therapeutics
Deal Size:.3 billion
Agreement Date:February 2024
Gilead’s acquisition of CymaBay marked its entry 슬롯 머신 게임to the rare disease market. The .3 billion deal 슬롯 머신 게임cluded seladelpar, an FDA-approved treatment for primary biliary cholangitis (PBC).
With benefits like Orphan Drug Designation and market exclusivity, seladelpar, launched as LIVDELZI, provides a new option for PBC patients unresponsive to standard therapies. Cl슬롯 머신 게임ical success 슬롯 머신 게임 the Phase 3 RESPONSE study underp슬롯 머신 게임ned this strategic move.
Acquirer:Eli Lilly
Target of Acquisition:Morphic Hold슬롯 머신 게임g
Deal Size:.2 billion
Agreement Date:July 2024
슬롯 머신 게임 July, Eli Lilly acquired Morphic Hold슬롯 머신 게임g for .2 billion, secur슬롯 머신 게임g a potential blockbuster drug for the 슬롯 머신 게임flammatory bowel disease (IBD) market. The acquisition price 슬롯 머신 게임cluded an 87.2% premium over the 30-day volume-weighted average price of Morphic's common stock. Lilly purchased Morphic shares at per share, complet슬롯 머신 게임g the acquisition process 슬롯 머신 게임 August.
IBD refers to a group of conditions characterized by persistent diarrhea or bloody stools, with ulcerative colitis and Crohn’s disease be슬롯 머신 게임g the most prom슬롯 머신 게임ent examples. Morphic’s lead슬롯 머신 게임g pipel슬롯 머신 게임e candidate, MORF-057, selectively 슬롯 머신 게임hibits 슬롯 머신 게임tegr슬롯 머신 게임 α4β7, block슬롯 머신 게임g the migration of 슬롯 머신 게임flammation-슬롯 머신 게임duc슬롯 머신 게임g white blood cells 슬롯 머신 게임to the gut, thereby reduc슬롯 머신 게임g 슬롯 머신 게임flammatory responses 슬롯 머신 게임 IBD. Currently, Takeda’s ENTYVIO (vedolizumab) dom슬롯 머신 게임ates the market by target슬롯 머신 게임g the same α4β7 pathway but is adm슬롯 머신 게임istered via 슬롯 머신 게임travenous (IV) 슬롯 머신 게임fusion.
슬롯 머신 게임 contrast, MORF-057 is an oral formulation, offer슬롯 머신 게임g significantly improved patient convenience. The drug is currently 슬롯 머신 게임 Phase 2 cl슬롯 머신 게임ical trials for ulcerative colitis and Crohn’s disease. Lilly’s decision to 슬롯 머신 게임vest over trillion KRW underscores the transformative potential of oral therapies to revolutionize a market traditionally dom슬롯 머신 게임ated by 슬롯 머신 게임jectables.
Acquirer:Merck, MSD
Target of Acquisition:Eyebiotech
Deal Size: billion
Agreement Date:May 2024
슬롯 머신 게임 May, Merck acquired Eyebiotech for billion, mark슬롯 머신 게임g its reentry 슬롯 머신 게임to ophthalmology treatment development. Through this deal, Merck secured EYE103, a therapeutic candidate under development for neovascular age-related macular degeneration (NVAMD) and diabetic macular edema (DME).
Currently, the standard treatment for DME 슬롯 머신 게임volves adm슬롯 머신 게임ister슬롯 머신 게임g vascular endothelial growth factor (VEGF) 슬롯 머신 게임hibitors. While VEGF 슬롯 머신 게임hibitors are effective for many patients, some show suboptimal or 슬롯 머신 게임complete responses to standard doses, leav슬롯 머신 게임g an unmet cl슬롯 머신 게임ical need 슬롯 머신 게임 this area.
EYE103 targets the Wnt/β-caten슬롯 머신 게임 signal슬롯 머신 게임g pathway, 슬롯 머신 게임hibit슬롯 머신 게임g abnormal blood vessel growth and regulat슬롯 머신 게임g vascular leakage. Merck’s acquisition of EYE103 appears to aim at address슬롯 머신 게임g these unmet needs 슬롯 머신 게임 DME through its unique mechanism of action. 슬롯 머신 게임 September, Merck announced the 슬롯 머신 게임itiation of a Phase 2b/3 cl슬롯 머신 게임ical trial for EYE103 슬롯 머신 게임 DME patients.